Company profile
PHARMING GROUP N.V.
NASDAQ:PHARBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| JOENJA | approved | — | 3 | approved |
| RUCONEST | approved | — | 0 | — |
| NAPAZIMONE | phase2 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (20)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02247739 | phase2 | completed | 2014-12-01 | 2016-05-01 | Pharming Technologies B.V. | A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor |
| NCT00851409 | phase2 | completed | 2009-06-01 | 2010-03-01 | Pharming Technologies B.V. | A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration |
| NCT06249997 | phase3 | unknown | 2023-08-03 | 2025-01-31 | Pharming Technologies B.V. | An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS |
| NCT05650229 | phase2 | recruiting | 2022-12-13 | 2027-10-01 | Pharming Technologies B.V. | Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease |
| NCT01188564 | phase3 | completed | 2011-01-01 | 2012-12-01 | Pharming Technologies B.V. | Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 217759 | 2023-03-24 | NDA | PHARMING TECHNOLOGIES BV | |||||
Loading… | ||||||||
| BLA 125495 | 2014-07-16 | BLA | PHARMING AMERICAS BV | |||||
Loading… | ||||||||